NEW YORK (GenomeWeb News) – Invitrogen has filed a formal notification with the European Commission regarding its pending $6.7 billion acquisition of Applied Biosystems, the firm said today.
The commission has 25 business days following the notification to respond to the filing, said Invitrogen. US regulatory authorities have already cleared the merger.
Invitrogen and ABI will hold a special meeting of shareholders on Oct. 16 to vote on the proposed deal. The firms expect to close the deal next month.